These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28404893)

  • 21. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
    J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.
    Nakai Y; Isayama H; Sasaki T; Takahara N; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1291-7. PubMed ID: 24121456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
    Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.
    Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA
    J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CA19-9 decrease and survival according to platelet level in patients with advanced pancreatic cancer.
    Chen Y; Wang YR; Deng GC; Dai GH
    BMC Cancer; 2019 Aug; 19(1):860. PubMed ID: 31470818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
    van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
    HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
    Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
    Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
    Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
    Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
    Klapdor R; Bahlo M; Babinski A; Klapdor S
    Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma.
    Shultz DB; Chan C; Shaffer JL; Kunz PL; Koong AC; Chang DT
    Pancreas; 2014 Jul; 43(5):777-83. PubMed ID: 24632549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.
    Månsson C; Nilsson A; Urdzik J; Karlson BM
    Anticancer Res; 2019 Nov; 39(11):6193-6196. PubMed ID: 31704847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma.
    Zhang H; Gao H; Liu C; Kong Y; Wang C; Zhang H
    Diagn Pathol; 2015 Mar; 10():13. PubMed ID: 25890028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.